CO2024000205A2 - Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones - Google Patents

Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones

Info

Publication number
CO2024000205A2
CO2024000205A2 CONC2024/0000205A CO2024000205A CO2024000205A2 CO 2024000205 A2 CO2024000205 A2 CO 2024000205A2 CO 2024000205 A CO2024000205 A CO 2024000205A CO 2024000205 A2 CO2024000205 A2 CO 2024000205A2
Authority
CO
Colombia
Prior art keywords
formulations
nanoemulsion particles
rna
lipid nanoemulsion
adsorbed
Prior art date
Application number
CONC2024/0000205A
Other languages
English (en)
Spanish (es)
Inventor
Sanjay Singh
Swarnendu Kaviraj
Ajay Singh
Arjun Singh Raghuwanshi
Pavan Kardile
Shalu Shukla
Aishwarya Kulkarni
Praveen Agrawal
Sunil Raut
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of CO2024000205A2 publication Critical patent/CO2024000205A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2024/0000205A 2021-07-13 2024-01-12 Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones CO2024000205A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121031414A IN202121031414A (https=) 2021-07-13 2021-07-13
PCT/IN2022/050624 WO2023286076A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations.

Publications (1)

Publication Number Publication Date
CO2024000205A2 true CO2024000205A2 (es) 2024-01-25

Family

ID=84920187

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0000205A CO2024000205A2 (es) 2021-07-13 2024-01-12 Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones

Country Status (11)

Country Link
US (1) US20240325522A1 (https=)
EP (1) EP4351521A4 (https=)
JP (1) JP2024525709A (https=)
KR (1) KR20240035836A (https=)
AU (1) AU2022310435A1 (https=)
CA (1) CA3226213A1 (https=)
CL (1) CL2024000120A1 (https=)
CO (1) CO2024000205A2 (https=)
IN (1) IN202121031414A (https=)
WO (1) WO2023286076A1 (https=)
ZA (1) ZA202400149B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
EP4405372A4 (en) 2021-09-22 2026-01-14 Hdt Bio Corp SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
KR20240096468A (ko) 2021-09-22 2024-06-26 에이치디티 바이오 코포레이션 감염병에 대한 rna 백신
TW202333780A (zh) * 2021-11-29 2023-09-01 德商拜恩技術股份公司 冠狀病毒疫苗
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation
KR20260032554A (ko) * 2023-06-29 2026-03-09 리그이뮨 아이엔씨. 신규한 제형

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840965C (en) * 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
JP2020524143A (ja) * 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用

Also Published As

Publication number Publication date
IN202121031414A (https=) 2023-01-13
EP4351521A1 (en) 2024-04-17
JP2024525709A (ja) 2024-07-12
WO2023286076A1 (en) 2023-01-19
US20240325522A1 (en) 2024-10-03
CA3226213A1 (en) 2023-01-19
ZA202400149B (en) 2024-08-28
AU2022310435A1 (en) 2024-01-25
CL2024000120A1 (es) 2024-08-16
KR20240035836A (ko) 2024-03-18
EP4351521A4 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
CO2024000205A2 (es) Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
SI3368507T1 (sl) Novi lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin
ZA202103233B (en) Lipid nanoparticle formulations
CO2021005774A2 (es) Lípidos con amina ionizables
MX2020003413A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
MX2024009845A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
CO2019007258A2 (es) Arn guía modificados
WO2022120388A3 (en) Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
MX2023008328A (es) Nanomateriales que comprenden una caracteristica biodegradable.
MX2023005696A (es) Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.
MX2019005470A (es) Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
MX377244B (es) Formulacion arn para inmunoterapia.
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
MX2022006512A (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
GT201400164A (es) Compuestos de imidazopirrolidinona
GT201500330A (es) Composiciones y métodos de uso de interferencia de arn en serpina 1
MX2025004779A (es) Formulaciones de proteinas de fusion vegfr-fc
TR201816986T4 (tr) Terapötik ajan iletim formülasyonlarına yönelik lipitler.
WO2013177421A3 (en) Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
PE20181131A1 (es) COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
UY35103A (es) Compuestos de cefem 2-sustituidos
MX2017012131A (es) Composiciones y métodos para la administración de agentes de biomacromoléculas.